Cart is empty The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
Leave A Comment